{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:45Z","timestamp":1791223905976,"version":"4.1.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,8]]},"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), represents a chronic progressive disease that imposes a significant burden on patients and the healthcare system. Linggui Zhugan decoction (LGZGD) plays a substantial role in treating NAFLD, but its exact molecular mechanism is unknown. Using network pharmacology, this study aimed to investigate the mechanism of action of LGZGD in treating NAFLD. Active ingredients and targets were identified through the integration of data from the TCMSP, GEO, GeneCards, and OMIM databases. Cytoscape 3.9.1 software, in conjunction with the STRING platform, was employed to construct network diagrams and screen core targets. The enrichment analysis of gene ontology and the Kyoto Encyclopedia of Genes and Genomes pathways were conducted by using the R. Molecular docking of the active ingredients and core targets was performed with AutoDock Vina software. We obtained 93 and 112 active ingredients and potential targets using the bioinformatic analysis of LGZGD in treating NAFLD. The primary ingredients of LGZGD included quercetin, kaempferol, and naringenin. The core targets were identified AKT1, MYC, HSP90AA1, HIF1A, ESR1, TP53, and STAT3. Gene ontology function enrichment analysis revealed associations with responses to nutrient and oxygen levels, nuclear receptor activity, and ligand-activated transcription factor activity. Kyoto Encyclopedia of Genes and Genomes signaling pathway analysis implicated the involvement of the PI3K-Akt, IL-17, TNF, Th17 cell differentiation, HIF-1, and TLR signaling pathways. Molecular docking studies indicated strong binding affinities between active ingredients and targets. LGZGD intervenes in NAFLD through a multi-ingredient, multi-target, and multi-pathway approach. Treatment with LGZGD can improve insulin resistance, oxidative stress, inflammation, and lipid metabolism associated with NAFLD.<\/jats:p>","DOI":"10.1097\/md.0000000000037281","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:06:15Z","timestamp":1709928375000},"page":"e37281","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Network pharmacological analysis on the mechanism of Linggui Zhugan decoction for nonalcoholic fatty liver disease"],"prefix":"10.1097","volume":"103","author":[{"given":"Songlin","family":"Gao","sequence":"first","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Wei","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwei","family":"Quan","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8412-9486","authenticated-orcid":false,"given":"Guihua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Spleen and Stomach Liver Diseases, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"e067203","DOI":"10.1136\/bmjopen-2022-067203","article-title":"Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III.","volume":"12","author":"Carrillo-Larco","year":"2022","journal-title":"BMJ Open"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","article-title":"The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol Int"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.3390\/ijms22126485","article-title":"Nonalcoholic fatty liver disease (NAFLD) as model of gut-liver axis interaction: from pathophysiology to potential target of treatment for personalized therapy.","volume":"22","author":"Fianchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease.","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019.","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020.","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"154893","DOI":"10.1016\/j.phymed.2023.154893","article-title":"The pharmacology and mechanisms of traditional Chinese medicine in promoting liver regeneration: a new therapeutic option.","volume":"116","author":"Ma","year":"2023","journal-title":"Phytomedicine"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1000727","DOI":"10.3389\/fendo.2022.1000727","article-title":"Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Pt B","key":"R11-20250503","first-page":"116927","article-title":"Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress.","volume":"318","author":"Gong","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1107071","DOI":"10.3389\/fendo.2022.1107071","article-title":"The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.","volume":"13","author":"Hui","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"116780","DOI":"10.1016\/j.jep.2023.116780","article-title":"Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro.","volume":"316","author":"Tang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R14-20250503","first-page":"222","article-title":"Advances in pharmacological mechanism of Linggui Zhugan Tang.","volume":"25","author":"Chen","year":"2019","journal-title":"Chin J Exp Tradit Medical Formulae"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s13063-020-04362-7","article-title":"Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: study protocol for a multicenter randomized controlled trial.","volume":"21","author":"Xu","year":"2020","journal-title":"Trials"},{"key":"R16-20250503","first-page":"199","article-title":"Huang Xiangwu\u2019s experience on treating nonalcoholic fatty liver disease with modified Linggui Zhugan Decoction.","volume":"38","author":"Zhou","year":"2020","journal-title":"Chin Arch Tradit Chin Med"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH.","volume":"26","author":"Raza","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"121185","DOI":"10.1016\/j.lfs.2022.121185","article-title":"Shedding light on non-alcoholic fatty liver disease: pathogenesis, molecular mechanisms, models, and emerging therapeutics.","volume":"312","author":"Khairnar","year":"2023","journal-title":"Life Sci"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ptr.8043","article-title":"Human diet-derived polyphenolic compounds and hepatic diseases: from therapeutic mechanisms to clinical utilization.","volume":"38","author":"Hu","year":"2024","journal-title":"Phytother Res"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/molecules28104080","article-title":"Application of polyphenols and flavonoids in oncological therapy.","volume":"28","author":"Roszkowski","year":"2023","journal-title":"Molecules"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"2199168","DOI":"10.1080\/14756366.2023.2199168","article-title":"Bioactivity and mechanisms of flavonoids in decreasing insulin resistance.","volume":"38","author":"Zhou","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/antiox12030663","article-title":"The potential of flavonoids and flavonoid metabolites in the treatment of neurodegenerative pathology in disorders of cognitive decline.","volume":"12","author":"Melrose","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"114991","DOI":"10.1016\/j.biopha.2023.114991","article-title":"The great potential of flavonoids as candidate drugs for NAFLD.","volume":"164","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1005312","DOI":"10.3389\/fphar.2022.1005312","article-title":"Natural flavonoids: potential therapeutic strategies for non-alcoholic fatty liver disease.","volume":"13","author":"Tan","year":"2022","journal-title":"Front Pharmacol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"112314","DOI":"10.1016\/j.fct.2021.112314","article-title":"Quercetin and non-alcoholic fatty liver disease: a review based on experimental data and bioinformatic analysis.","volume":"154","author":"Chen","year":"2021","journal-title":"Food Chem Toxicol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12944-021-01590-x","article-title":"Protective effect of quercetin against the metabolic dysfunction of glucose and lipids and its associated learning and memory impairments in NAFLD rats.","volume":"20","author":"Gao","year":"2021","journal-title":"Lipids Health Dis"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"876550","DOI":"10.3389\/fphar.2022.876550","article-title":"Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity.","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1039\/D0FO02123G","article-title":"Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis.","volume":"11","author":"Lu","year":"2020","journal-title":"Food Funct"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.3390\/ijms22168847","article-title":"Kaempferol and kaempferide attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells.","volume":"22","author":"Tie","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice.","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"687095","DOI":"10.3389\/fphar.2021.687095","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by enhancing energy expenditure and regulating autophagy via AMPK.","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/advances\/nmaa106","article-title":"A comprehensive systematic review of the effects of naringenin, a citrus-derived flavonoid, on risk factors for nonalcoholic fatty liver disease.","volume":"12","author":"Naeini","year":"2021","journal-title":"Adv Nutr"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/RMHP.S416592","article-title":"Genetic variations of AKT1 are associated with risk screening for non-alcoholic fatty liver disease.","volume":"16","author":"Ding","year":"2023","journal-title":"Risk Manag Healthc Policy"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1038\/ncomms8079","article-title":"FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization.","volume":"6","author":"O-Sullivan","year":"2015","journal-title":"Nat Commun"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"6254340","DOI":"10.1155\/2018\/6254340","article-title":"Enhancement of adiponectin ameliorates nonalcoholic fatty liver disease via inhibition of FoxO1 in Type I Diabetic Rats.","volume":"2018","author":"Xie","year":"2018","journal-title":"J Diabetes Res"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1080\/21655979.2022.2037374","article-title":"Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification.","volume":"13","author":"Jiang","year":"2022","journal-title":"Bioengineered"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2023.05.100","article-title":"USP33 promotes nonalcoholic fatty acid disease-associated fibrosis in gerbils via the c-myc signaling.","volume":"669","author":"Ke","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s42255-021-00421-8","article-title":"Intestinal MYC modulates obesity-related metabolic dysfunction.","volume":"3","author":"Luo","year":"2021","journal-title":"Nat Metab"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1194\/jlr.M048918","article-title":"Hsp90 modulates PPAR\u03b3 activity in a mouse model of nonalcoholic fatty liver disease.","volume":"55","author":"Wheeler","year":"2014","journal-title":"J Lipid Res"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/hep.30215","article-title":"Macrophage-specific Hypoxia-inducible factor-1\u03b1 contributes to impaired autophagic flux in nonalcoholic steatohepatitis.","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"e2301485","DOI":"10.1002\/adhm.202301485","article-title":"Carbon nitride-based siRNA vectors with self-produced O2 effects for targeting combination therapy of liver fibrosis via HIF-1\u03b1-mediated TGF-\u03b21\/Smad pathway.","volume":"18","author":"Liu","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"R43-20250503","first-page":"1575","article-title":"Effects of Heye granule on lipid metabolism and SREBP-1c expression in nonalcoholic fatty liver rats based on HIF-1\u03b1\/PPAR\u03b3.","volume":"49","author":"Ye","year":"2020","journal-title":"Chongqing Med"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1152\/ajpendo.00259.2018","article-title":"Estrogen receptor-\u03b1 signaling maintains immunometabolic function in males and is obligatory for exercise-induced amelioration of nonalcoholic fatty liver.","volume":"316","author":"Winn","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molmet.2019.10.002","article-title":"Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer.","volume":"33","author":"Lacroix","year":"2020","journal-title":"Mol Metab"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"117086","DOI":"10.1016\/j.lfs.2019.117086","article-title":"Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway.","volume":"241","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12072-020-10068-4","article-title":"Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction.","volume":"14","author":"Zhang","year":"2020","journal-title":"Hepatol Int"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.30919","article-title":"CREBZF as a key regulator of STAT3 pathway in the control of liver regeneration in mice.","volume":"71","author":"Hu","year":"2020","journal-title":"Hepatology"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.jhepr.2022.100628","article-title":"Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.","volume":"5","author":"Jiao","year":"2022","journal-title":"JHEP Rep"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"472432","DOI":"10.1155\/2013\/472432","article-title":"Roles for PI3K\/AKT\/PTEN pathway in cell signaling of nonalcoholic fatty liver disease.","volume":"2013","author":"Matsuda","year":"2013","journal-title":"ISRN Endocrinol"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1039\/D0FO02736G","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD.","volume":"12","author":"Li","year":"2021","journal-title":"Food Funct"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"114005","DOI":"10.1016\/j.biopha.2022.114005","article-title":"Induction of autophagy via the PI3K\/Akt\/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice.","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R53-20250503","first-page":"517","article-title":"Effects of Salvia mil on Th17 cells and related cytokines in non-alcoholic fatty liver disease.","volume":"35","author":"Cui","year":"2019","journal-title":"Chin J Appl Physiol"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"e0368821","DOI":"10.1128\/mbio.03688-21","article-title":"Interleukin-17 weakens the NAFLD\/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota.","volume":"13","author":"He","year":"2022","journal-title":"mBio"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgg.2021.09.009","article-title":"Tumor necrosis factor-\u03b1 signaling in nonalcoholic steatohepatitis and targeted therapies.","volume":"49","author":"Lu","year":"2022","journal-title":"J Genet Genomics"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1165\/rcmb.2020-0492OC","article-title":"Hepatocyte HIF-1 and intermittent hypoxia independently impact liver fibrosis in murine nonalcoholic fatty liver disease.","volume":"65","author":"Mesarwi","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4254\/wjh.v8.i32.1354","article-title":"Toll-like receptors in pathophysiology of liver diseases.","volume":"8","author":"Kiziltas","year":"2016","journal-title":"World J Hepatol"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.","volume":"185","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol Res"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/jcmm.13636","article-title":"The TLR4-IRE1\u03b1 pathway activation contributes to palmitate-elicited lipotoxicity in hepatocytes.","volume":"22","author":"Shen","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R60-20250503","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.21037\/atm-21-4012","article-title":"TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells.","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:21:29Z","timestamp":1746318089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037281","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}